Olaparib Misses Mark in Recurrent Platinum-Sensitive Ovarian Cancer
Olaparib did not significantly improve overall survival compared with chemotherapy in recurrent, platinum-sensitive ovarian cancer.
Acalabrutinib Associated With Fewer Cardiac Toxicities Than Ibrutinib in CLL Treatment
An analysis of 3 randomized trials showed that acalabrutinib was associated with approximately half the number of cardiac toxicities than with comparator treatments.
Immunotherapy-Based Regimens Are Associated With OS Advantage in HCC
Immuno-oncology regimens were linked with improved long-term survival among patients with hepatocellular carcinoma.
MET+ Expression May Help Guide Treatment Decisions With Amivantamab/Lazertinib in Post-Osimertinib NSCLC
Patients with EGFR-mutated non–small cell lung cancer and MET positivity may derive greater benefit from amivantamab plus lazertinib than patients who are MET-negative.
Heavily Pretreated Patients With Richter Syndrome Achieved Antitumor Activity With Glofitamab
Glofitamab monotherapy led to a 63.6% overall response rate in heavily pretreated patients with Richter syndrome.
Neoadjuvant Enfortumab Vedotin Associated With Substantial Antitumor Activity in Muscle-Invasive Bladder Cancer
The rate of pathologic complete responses with enfortumab vedotin was 36.4% among patients with muscle-invasive bladder.
Nirogacestat Significantly Reduces Pain Severity in Patients With Desmoid Tumors
Nirogacestat significantly reduced pain scores for patients with desmoid tumors.
Patients With De Novo or Late Recurrent Metastatic HR+ Breast Cancer Derive OS Benefit From Ribociclib/Letrozole
A subgroup analysis showed that patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy achieved better outcomes with ribociclib plus letrozole.
Aumolertinib Plus SRT Achieves Intracranial Responses in Oligometastatic EGFR+ NSCLC
Prospective phase 2 data demonstrated that aumolertinib, followed by salvage stereotactic radiation therapy, elicited responses in patients with intracranial oligometastatic EGFR-mutant non–small cell lung cancer.
Endocrine Therapy Plus Ovarian Suppression Remains An Effective Treatment Strategy in HR+, HER2-, Early Breast Cancer
Investigators Present Real-World Experiences With T-DXd Following HER2 Status Changes
Maintenance Pembrolizumab/Olaparib Falls Short in Locally Advanced, Metastatic TNBC
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
2 Clarke Drive Cranbury, NJ 08512